Generic Name and Formulations:
Trivalent inactivated "split virus" influenza vaccine (Types A and B); formulation changes annually; susp for IM inj; contains thimerosal.
Novartis Pharmaceuticals Corp
Indications for FLUVIRIN:
Adults and Children:
<4yrs: not recommended. Each dose is 0.5mL IM. 4–8yrs: 2 doses at least 1 month apart for 1st immunization, otherwise 1 dose per season. >9yrs: 1 dose/season. Infants and young children: give in anterolateral thigh; older: give in deltoid muscle.
Allergy to egg proteins. Life-threatening reaction to any previous flu vaccine.
Use current formulation only. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunosuppressed. Have epinephrine inj (1:1000) available. Pregnancy (Cat.C). Nursing mothers.
Concomitant vaccines: insufficient data (see literature). Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids) may result in suboptimal response.
Local reactions, headache, fever, malaise, fatigue, myalgia.
Multidose vial (5mL)—1
Single-dose prefilled syringes (0.5mL)—10
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Expert Roundtable: AHA Update on Dietary Fat Intake and CVD Risk
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation